| Status | Study |
| Enrolling by invitation |
Study Name: Expression of Protein Convertases in Thyroid Nodules Condition: Thyroid Nodule Date: 2017-05-16 Interventions: Diagnostic Test: Immunohistochemistry Immunohistochemistry procedure on the formalin-fixed, paraffin-emb |
| Not yet recruiting |
Study Name: Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Condition: Columnar Cell Variant Thyroid Gland Papillary Carcinoma Follicular Variant Thyroid Gland Pap Date: 2016-11-23 Interventions: Other: Laboratory Biomarker Analysis |
| Not yet recruiting |
Study Name: Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Condition: Thyroid Cancer Date: 2016-07-27 |
| Recruiting |
Study Name: Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Condition: Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Date: 2015-03-16 Interventions: Radiation: Iodine I-131 Given |
| Recruiting |
Study Name: Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Condition: BRAF Gene Mutation Poorly Differentiated Thyroid Gland Carcinoma Date: 2014-05-29 Interventions: Procedure: Computed Tomography |
| Suspended |
Study Name: Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Condition: Papillary Carcinoma of Thyroid Metastatic to Regional Lymph Node Metastatic Medullary Thyroi Date: 2013-08-20 Interventions: Drug: Ferumoxytol Ferumoxytol |
| Suspended |
Study Name: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Condition: Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Date: 2013-03-12 Interventions: Drug: Cabozantinib S-malate Gi |
| Active, not recruiting |
Study Name: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Condition: Follicular Thyroid Cancer Insular Thyroid Cancer Date: 2012-10-22 Interventions: Drug: dabrafenib 150 mg orally |
| Recruiting |
Study Name: Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Condition: Colorectal Cancer Gastric Adenocarcinoma Esophageal Cancer Date: 2012-06-26 Interventions: Drug: IMMU-132 IMMU-132 is administered on days 1 & 8 of 3 week treatment cycles. Up to 8 cycles wil |
| Completed |
Study Name: Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment Condition: Malignant Struma Ovarii Papillary Thyroid Cancer Hurthle C Date: 2011-09-24 |